Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740516 | 0.87 | FPR2 (0.33) | — | |
| SCHEMBL2503280 | 0.82 | FPR2 (0.39) | ESR1SMN1; SMN2 | |
| SCHEMBL1740513 | 0.80 | FPR2 (0.35) | — | |
| SCHEMBL15335282 | 0.79 | ALPL (0.46) | SMN1; SMN2 | |
| SCHEMBL18030075 | 0.78 | FPR2 (0.43) | ESR1SMN1; SMN2 | |
| SCHEMBL15899642 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL15094787 | 0.77 | — | — | |
| SCHEMBL15199209 | 0.77 | ALPG (0.48) | ESR1SMN1; SMN2 | |
| SCHEMBL13233456 | 0.75 | SMN1; SMN2 (0.35) | ESR1SMN1; SMN2 | |
| SCHEMBL19964722 | 0.74 | PDE4A (0.35) | ESR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739316-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013022797-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2013-02-14 | — | — | WO | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2389361-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-2373622-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065902-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | CA9, CA13, CA14 | ESR1 3943/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.